The University of Chicago (UChicago) Institute for Translational Medicine (ITM) was created in 2007 to assemble, integrate, and create the intellectual, administrative, and physical resources required to catalyze research and research training in Clinical and Translational Science. We have trained university scientists and health care providers to work together with stakeholders in all concerned communities to determine the molecular, genetic, pathophysiologic, and social determinants of disease; to develop and test interventions directed toward those mechanisms; and to achieve these goals in a way that is rigorous, efficient, ethical, respectful of, and responsive to our community?s needs and values. In its first 9 years, the ITM has capitalized on outstanding intellectual and physical resources throughout UChicago and at ITM affiliate institutions ? Rush University Medical Center (Rush), NorthShore University HealthSystem (NorthShore), and Illinois Institute of Technology (IIT) ? to build the infrastructure for a transformative, energized, and self-improving home for clinical and translational research. Now, we pursue a bold guiding vision for ?ITM 2.0? ? that health outcomes will be improved throughout Chicagoland by mitigating disease risk, morbidity and mortality through collaborative, multidisciplinary team science. We will work toward this vision by assembling scientific, institutional, and community stakeholders, and together focusing on the highest value propositions to improve mutually defined health concerns, leveraging synergies that accelerate progress across the translational spectrum. Our core conviction is that participating in health research is a matter of shared self-interest and social justice, a ?new normal? prevailing viewpoint toward which we will strive together over the next 20 years. ITM 2.0 will work hand-in-hand with health stakeholders throughout Chicagoland and throughout the nation, conceptualizing, developing and deploying innovative processes and practices to achieve our common goal. Preparing for this ambitious challenge, we broadened the scope of institutional and community stakeholders. Rush now joins UChicago as an ITM lead institution, and Loyola University Medical Center and Advocate Health Care join as ITM affiliates. We partner with esteemed institutions ? the Chicago Community Trust, the Illinois Biotechnology Industry Organization, and the Chicago and Illinois Departments of Public Health ? and inclusively leverage strong collaborations with the other two Chicago CTSAs, with the Chicago-wide PCORnet CDRN CAPriCORN, and with the recently awarded Illinois Precision Medicine Consortium. In ITM 2.0, we will together develop innovative and sometimes disruptive approaches to advance the science and practice of clinical and translational research by rigorously determining which approaches work and then disseminating the results of both successes and failures. We expect that this approach will improve the conduct of and training for clinical and translational research for the benefit of Chicago, the CTSA Consortium, and the nation.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
5UL1TR002389-02
Application #
9559734
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Rosemond, Erica
Project Start
2017-09-06
Project End
2022-06-30
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Lanning, Monica S; Carmody, David; Szczerbi?ski, ?ukasz et al. (2018) Hypoglycemia in sulfonylurea-treated KCNJ11-neonatal diabetes: Mild-moderate symptomatic episodes occur infrequently but none involving unconsciousness or seizures. Pediatr Diabetes 19:393-397
Zalta, Alyson K; Held, Philip; Smith, Dale L et al. (2018) Evaluating patterns and predictors of symptom change during a three-week intensive outpatient treatment for veterans with PTSD. BMC Psychiatry 18:242
Harris, Anastasia G; Letourneau, Lisa R; Greeley, Siri Atma W (2018) Monogenic diabetes: the impact of making the right diagnosis. Curr Opin Pediatr 30:558-567
Carroll, Kathryn K; Lofgreen, Ashton M; Weaver, Darian C et al. (2018) Negative posttraumatic cognitions among military sexual trauma survivors. J Affect Disord 238:88-93
Dickens, Laura T; Naylor, Rochelle N (2018) Clinical Management of Women with Monogenic Diabetes During Pregnancy. Curr Diab Rep 18:12
Horwitz, Adam G; Held, Philip; Klassen, Brian J et al. (2018) Posttraumatic Cognitions and Suicidal Ideation among Veterans receiving PTSD Treatment. Cognit Ther Res 42:711-719
Cheng, Jason X; Chen, Li; Li, Yuan et al. (2018) RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun 9:1163
Letourneau, Lisa R; Greeley, Siri Atma W (2018) Congenital Diabetes: Comprehensive Genetic Testing Allows for Improved Diagnosis and Treatment of Diabetes and Other Associated Features. Curr Diab Rep 18:46
Prochaska, Micah T; Newcomb, Richard; Jiang, David et al. (2018) The effect of red-blood-cell transfusion on fatigue in hospitalized patients with anaemia. Vox Sang 113:669-677
Letourneau, Lisa R; Greeley, Siri Atma W (2018) Congenital forms of diabetes: the beta-cell and beyond. Curr Opin Genet Dev 50:25-34

Showing the most recent 10 out of 14 publications